Ernexa Therapeutics filings document a Delaware biotechnology issuer developing synthetic allogeneic iMSC cell therapies and reporting as a public company with common stock and common stock purchase warrants listed on Nasdaq. Registration statements and amendments disclose the company's cellular-therapy business, operating and financial results, capital structure, risk factors, clinical and regulatory development disclosures, and offering-related security terms.
Current reports on Form 8-K cover material events including amendments to the certificate of incorporation for a 1-for-25 reverse stock split, Nasdaq minimum-bid compliance notices, Regulation FD investor-presentation materials, changes in the independent registered public accounting firm, going-concern explanatory disclosures and internal-control matters.
Ernexa Therapeutics Inc. (ERNA) reported that director Elena Ratner received a grant of stock options covering 5,944 shares of common stock at an exercise price of $4.57 per share. Subject to continued service, one-third of the option vests on the first anniversary of the grant date, with the remaining two-thirds vesting in 24 substantially equal monthly installments through August 31, 2036.
Ernexa Therapeutics Inc. (ERNA) reported that President and CEO Luther Sanjeev received a grant of stock options. The award covers 118,848 options to acquire Ernexa common shares at an exercise price of $4.57 per share, expiring on 2036-08-31. Following this grant, Sanjeev holds 118,848 derivative securities of this type.
The options vest over time: one-third of the underlying shares vest on the first anniversary of the grant date, with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter, subject to continued service.
Ernexa Therapeutics Inc. (ERNA) reported the initial equity holdings of director David Polinsky. He indirectly holds a warrant, through Polo3K, LLC, to purchase 8,000 shares of Common Stock at an exercise price of $17.00 per share, and indirectly holds 8,000 shares of Common Stock.
The warrant is scheduled to expire on February 10, 2031, but will instead expire earlier if triggered by clinical milestones: specifically, on the 180th calendar day following public release of clinical trial data from the first cohort of the Phase 1 study of ERNA-101.
Ernexa Therapeutics Inc., a pre-clinical iMSC cell-therapy company, reported a six-month net loss of $9.5 million to June 30, 2026, driven by $4.7 million in research and development as it advances lead oncology candidate ERNA‑101 and autoimmune program ERNA‑201. General and administrative expense was $2.9 million and a $2.0 million goodwill impairment eliminated all goodwill.
Cash was approximately $5.0 million at June 30, 2026 and about $7.4 million by August 4, after a February public offering delivering $9.5 million in net proceeds and subsequent ATM sales of 461,851 shares for $3.7 million. Management notes this cash is below forecast needs for the next 12 months and plans to rely on remaining ATM capacity under a $50.0 million shelf. During the quarter Ernexa completed a 1‑for‑25 reverse stock split to regain Nasdaq bid‑price compliance and recognized a $41,000 gain from extinguished contingent consideration. An independently run preclinical study in July 2026 reproduced ERNA‑101’s complete tumor clearance and durable survival in ovarian cancer models, supporting an IND filing planned for 2026 and a first‑in‑human Phase 1 trial thereafter.
Ernexa Therapeutics Inc. furnished an updated investor presentation as part of a current report on Form 8-K. The July 2026 presentation, attached as Exhibit 99.1, updates materials first posted in February 2026 and will also be available on the company’s investor relations website.
The company states that it routinely uses its website to distribute important information, including press releases, investor presentations and financial data, and offers email alerts when new materials are posted. The information in this item and Exhibit 99.1 is being provided as “furnished,” not “filed,” under the Exchange Act.
Ernexa Therapeutics Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of the May 6, 2026 record date, there were 1,166,333 common shares outstanding, and 619,741 shares, or about 53.13%, were represented, establishing a quorum.
Stockholders elected five directors to serve until the 2027 annual meeting, ratified Haskell & White LLP as independent auditor for the 2026 fiscal year, and approved the 2026 Ernexa Therapeutics Inc. Omnibus Equity Incentive Plan. No other matters were brought to a vote.
Ernexa Therapeutics Inc. announced that Senior Vice President of Finance Sandra Gurrola has submitted her resignation, effective July 3, 2026. The company states that her resignation is not due to any disagreement over operations, policies, or practices.
After her resignation becomes effective, Ms. Gurrola has agreed to provide transition assistance on a part-time basis for up to 10 hours per week through the filing of Ernexa’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Ernexa has begun a search for her successor and plans to use additional outside support to help with finance, accounting, and reporting until a replacement is appointed.
Ernexa Therapeutics Inc. received an amendment to a Schedule 13G filed by Clear Street LLC that terminates Clear Street's reporting obligation. The amendment states Clear Street's beneficial ownership is 0 shares, representing 0.0% of the common stock and therefore below the 5% reporting threshold.
The amendment explains no reporting obligation existed at the time of the original filing and is signed by John DiBacco, Head of Markets Trading on 05/20/2026.
Freebird Partners LP and related reporting persons amend a Schedule 13G/A to report beneficial ownership of Ernexa Therapeutics Inc. common stock. The filing shows 120,412 shares beneficially owned, representing 9.9% of the class, based on an aggregate outstanding share count of 1,205,328 shares as of May 8, 2026. The reported position combines 81,417 owned shares and shares issuable on exercise of warrants (including 52,000 common warrants and 15,015 pre-funded warrants), with 28,020 warrant shares excluded because of a contractual 9.99% beneficial ownership limitation. The coverages reflect the issuer's 1-for-25 reverse stock split effected May 4, 2026.
Ernexa Therapeutics Inc. disclosure amends prior Schedule 13G filings to report that John D. Halpern and Katherine H. Halpern, as trustees of the John D. Halpern Revocable Trust, share beneficial ownership of 66,751 shares of Common Stock, representing 5.6% of the class.
The filing explains the share count includes (i) 46,445 shares held by the Trust, (ii) 306 shares issuable upon exercise of pre-funded warrants at an exercise price of $1.8750 per share, and (iii) 20,000 shares issuable upon exercise of warrants at $17.00 per share. The percentage is calculated using an aggregate of 1,186,639 shares outstanding (including 20,306 shares issuable within 60 days), and notes the impact of the 1-for-15 and 1-for-25 reverse stock splits.